Involvement of anti-tumor miR-124-3p and its targets in the pathogenesis of pancreatic ductal adenocarcinoma: direct regulation of ITGA3 and ITGB1 by miR-124-3p

Tetsuya Idichi,Naohiko Seki,Hiroshi Kurahara,Haruhi Fukuhisa,Hiroko Toda,Masataka Shimonosono,Yasutaka Yamada,Takayuki Arai,Yoshiaki Kita,Yuko Kijima,Yuko Mataki,Kosei Maemura,Shoji Natsugoe

DOI: https://doi.org/10.18632/oncotarget.25599

2018-06-22

Oncotarget

Abstract:MicroRNAs (miRNAs) are unique in that a single miRNA molecule regulates a vast number of RNA transcripts. Thus, aberrantly expressed miRNAs disrupt tightly controlled RNA networks in cancer cells. Our functional screening showed that expression of <i>miR-124-3p</i> was downregulated in pancreatic ductal adenocarcinoma (PDAC) tissues. Here, we aimed to investigate the anti-tumor roles of <i>miR-124-3p</i> in PDAC cells and to identify <i>miR-124-3p</i>-mediated oncogenic signaling in this disease. Ectopic expression of <i>miR-124-3p</i> inhibited cancer cell migration and invasion in PDAC cells. Moreover, restoration of <i>miR-124-3p</i> suppressed oncogenic signaling, as demonstrated by reduced phosphorylation of focal adhesion kinase, AKT, and extracellular signal-regulated kinase, in PDAC cells. Our <i>in silico</i> database analyses and luciferase reporter assays showed that two cell-surface matrix receptors, integrin α3 (<i>ITGA3</i>) and integrin β1 (<i>ITGB1</i>), were directly regulated by <i>miR-124-3p</i> in PDAC cells. Overexpression of <i>ITGA3</i> and <i>ITGB1</i> was confirmed in PDAC clinical specimens. Interestingly, a large number of cohort analyses from TCGA database showed that high expressions of <i>ITGA3</i> and <i>ITGB1</i> were significantly associated with poor prognosis of patients with PDAC. Knockdown of <i>ITGA3</i> and <i>ITGB1</i> by siRNAs markedly suppressed the migration and invasion abilities of PDAC cells. Moreover, downstream oncogenic signaling was inhibited by ectopic expression of <i>miR-124-3p</i> or knockdown of the two integrins. The discovery of anti-tumor miRNAs and miRNA-mediated oncogenic signaling may provide novel therapeutic targets for the treatment of PDAC.